0531: Retrospective monocentric study of coronary bifurcation lesions treated with a dedicated stent Nile Pax

Abstract

To demonstrate the acute and early outcomes of the Nile PAX dedicated polymer-free paclitaxel-coated stents in the treatment of the coronary bifurcation lesions. The Nile PAX device incorporates a cobalt-chromium alloy with a side aperture in the mid-stent designed to optimize scaffold at the bifurcation carina and side branch (SB) ostium, while maintaining SB access during procedure. From January 2012 to December 2014, 36 patients were included in a retrospective, monocentric study. Lesion criteria were: vessel size 2.5-3.5mm in the parent vessel (PV) and 2.0-3.0mm in the SB, regardless of the lesion length. Average age was 63,1 years, 22% of patientshad diabetesand 51% had acute coronary syndrome, while LAD/Dg was involved in 67% of cases. Percutaneous coronary intervention (PCI) Ad-Hoc was done for 40%of lesions. SB received additional stent in 8% of procedures and final kissing-balloon inflation was performed in 89% of procedures. There was three non-Q myocardial infarctions: one during hospitalization, and two up to 6 months.In addition to these three Major adverse cardiacevents (MACE), two other patients underwent a target lesion revascularization due to astable angina. Preliminary results of this retro-prospective monocentric study demonstrated encouraging results with the Nile PAX bifurcation DES in the treatment of coronary bifurcation lesions, including high device and procedural success.